Trial Profile
A Registry of Patients With Moderate to Severe Chronic Plaque Psoriasis in Canada and Latin AmErica (LACan)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Acronyms PURE
- Sponsors Novartis Pharmaceuticals
- 23 Dec 2022 Results assessing Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis, published in the Dermatology and Therapy
- 10 Dec 2022 Results (n=187) assessing effectiveness and safety outcomes with secukinumab and other treatment for plaque psoriasis for up to 12 months in a Latin American population,published in the Dermatology and Therapy
- 30 Apr 2021 Planned End Date changed from 30 Dec 2025 to 31 Dec 2025.